Does Thrombin Activatable Fibrinolysis Inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?

Thrombosis and Haemostasis

Volumn 88, Issue 4, 2002, Pages 644-647

  Antovic, Jovan P ^a   Hamad, R Rafik ^a   Antovic, A ^a   Blomback M ^a   Bremme, K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clot lysis time; Overall fibrinolytic potential in plasma (OFP); Preeclampsia; TAFI antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIGEN; ASPARTATE AMINOTRANSFERASE; CREATININE; GLYCOPROTEIN; SERUM ALBUMIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; AMINOTRANSFERASE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOSYNTHESIS; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IMMUNOASSAY; INTRAUTERINE GROWTH RETARDATION; LIVER METABOLISM; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEINURIA; THROMBOSIS; URINARY EXCRETION; BLOOD; CASE CONTROL STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ADULT; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; FIBRINOLYSIS; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; SERUM ALBUMIN; TRANSAMINASES;

EID: 0036796216     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613269     Document Type: Article

References (22)

1. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
2. Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
3. Bajzar L, Morser J, Neisheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
4. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
5. Wang W, Boffa MB, Bajzar L, Walker JB, Neisheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
6. Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with hemophilia A. Haemophilia 2001; 7: 557-60.
7. Van Thiei DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-70.
8. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
9. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95: 2855-9.
10. Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 518-23.
11. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104: 1-6.
12. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
13. Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115: 150-2.
14. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-6.
15. Perry KG Jr, Martin JN Jr. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol 1992; 35: 338-50.
16. Schjetlein R, Haugen G, Wisllow F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76: 541-6.
17. Sheppard BL and Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Sem Thromb Hemost 1999; 25: 443-6.
18. Gilabert J, Estelles A, Grancha S, Espana F, Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in preeclampsia. Hum Reprod 1995; 10 (Suppl. 2): 121-31.
19. He S, Bremme K, Blombäck M. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia. Blood Coagul Fibrinolysis 1995; 6: 703-8.
20. Kanfer A, Bruch JF, Ngyen G et al. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 1996; 74: 253-8.
21. He S, Antovic A, Blomback M. A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma II. Modifications for Use in Routine Laboratories and Research Work. Thromb Res 2001; 103: 355-61.
22. He S, Bremme K, Blomback M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Fibrinolysis 1997; 8: 232-8.